Skip to main content

Table 4 Subgroup analyses of the association between TZDs and AF

From: Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis

Subgroup

Study

Number of studies

Heterogeneity

Meta-analysis

I2

P-Value

OR

95% CI

p-Value

AF types

New-onset AF

4

0%

0.64

0.77

0.65–0.91

0.002

Recurrent AF

2

0%

0.54

0.41

0.24–0.72

0.002

TZDs

Solely pioglitazone

3

54%

0.11

0.56

0.32–0.98

0.04

Solely rosiglitazone

2

34%

0.22

0.78

0.57–1.07

0.12

Follow-up duration

≤ 5 years

4

34%

0.21

0.62

0.41–0.94

0.02

> 5 years

3

0

0.47

0.76

0.63–0.91

0.002

Study design

RCTs

3

40%

0.10

0.77

0.53–1.12

0.17

Observational studies

4

0%

0.41

0.71

0.59–0.85

0.0003

  1. Abbreviations: TZDs thiazolidinediones, AF atrial fibrillation, RCTs randomized controlled trials, OR odds ratio, CI confidence interval